[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345329-105":59,"doc-detail-345329-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","enhanced-multicancer-screening-assay-through-whole-genome-methylation-sequencing-based-multimodal-cell-free-dna-analysis","Enhanced multicancer screening assay through whole-genome methylation sequencing-based multimodal cell-free DNA analysis","","Enhanced multicancer screening remains challenging due to the low abundance and heterogeneity of circulating tumor DNA, particularly for stage I cancers. This study presents an enhanced multicancer screening assay integrating whole-genome methylation sequencing with a multimodal analysis framework for cell-free DNA. An ensemble machine learning model combines average methylation fraction, copy number variation, fragment size ratio, and fragment size distribution. Evaluation on 1,415 samples covering eight cancer types and controls yields 93.2% sensitivity and 95% specificity, with stage I sensitivity 92.3% and stage II 92.2%.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enhanced-multicancer-screening-assay-through-whole-genome-methylation-sequencing-based-multimodal-cell-free-dna-analysis/345329/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enhanced-multicancer-screening-assay-through-whole-genome-methylation-sequencing-based-multimodal-cell-free-dna-analysis/345329.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is early-stage multicancer detection difficult with circulating tumor DNA?","Question",{"text":112,"@type":113},"Low concentration and heterogeneous characteristics of circulating tumor DNA make detection, especially for stage I disease, challenging.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are the four cfDNA characteristics integrated in the ensemble model?",{"text":117,"@type":113},"The model integrates average methylation fraction, copy number variation, fragment size ratio, and fragment size distribution.",{"name":119,"@type":110,"acceptedAnswer":120},"How well does the assay perform for early-stage cancers?",{"text":121,"@type":113},"Sensitivity is 92.3% for stage I and 92.2% for stage II, indicating effectiveness in detecting early-stage cancers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345329,1790197537,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www.nature.com/emm](www.nature.com/emm)  \nARTICLE OPEN   \nEnhanced multicancer screening assay through whole-genome methylation sequencing-based multimodal cell-free DNA analysis  \nSeongmun Jeong 1, Dayoung Go 1, Yujin Jeon 1, Yong-Jin Kim1, Hayoon Lee1, Young-Woo Kim2, Hyun Goo Woo 3, Joo Kyung Park4, Young Tae Kim 5, Young Sik Park6, Se-Hoon Lee 7,8, Wonshik Han 9, Han-Byoel Lee9, Kwang Hyun Kim10, Sanghoo Lee11, Sungho Kim12, Sang-Hyun Song1, Hwang-Phill Kim1, Yongjun Cha1, Duhee Bang 13 and Tae-You Kim1,14,15 ✉  \n© The Author(s) 2026  \n\n|  | The rapid and accurate detection of multiple cancers presents considerable challenges, especially for stage I disease, due to the low concentration and heterogeneous nature of circulating tumor DNA. Here we introduce an enhanced multicancer screening assay that integrates whole-genome methylation sequencing with an innovative multimodal analytical framework for cell-free DNA. The ensemble machine learning model integrates four speciﬁc cell-free DNA characteristics: average methylation fraction, copy number variation, fragment size ratio and fragment size distribution. The model underwent testing on 1415 samples, encompassing eight primary cancer types and healthy controls. The sensitivity was 93.2%, and the speciﬁcity was 95% . The test demonstrated effectiveness in detecting cancers at early stages. The sensitivity was 92.3% for stage I and 92.2% for stage II. The multimodal technique successfully combined average methylation fraction’s sensitivity to early epigenetic signals with fragmentomic characteristics. This facilitated the differentiation between healthy individuals and those with early stage cancer. The model achieved an accuracy rate of 85.7% in the top 2 category for correctly identifying the tissue of origin. The results conﬁrm that whole-genome methylation sequencing-based multimodal analysis can improve multicancer early detection technology and |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| revolutionize cancer screening methods. |  |  |\n|  | Experimental & Molecular Medicine (2026) 58:1311–1324; [https://doi.org/10.1038/s12276-026-01674-7](https://doi.org/10.1038/s12276-026-01674-7) |  |\n|  |  |  |\n\nINTRODUCTION  \nCancer continues to be a primary cause of mortality globally, with more than 20 million new cases and nearly 9.7 million deaths reported annually1,2. Early detection is essential for enhancing survival rates and optimizing treatment outcomes, as prompt intervention facilitates curative treatment3 and mitigates the challenges associated with late-stage diagnosis. Conventional screening methods, including imaging and tissue biopsy, are often invasive, costly and limited in their capacity to concurrently detect multiple cancer types, despite the signiﬁcance of early detection4. In addition, numerous high-mortality cancers, such as pancreatic, ovarian and prostate cancers, do not have established screening guidelines, leading to late-stage diagnoses and unfavorable prognoses5. Furthermore, it has been demonstrated that MCED tests can detect a broad range ofearly-stage cancers that lack  \nUSPSTF-recommended screening protocols6. These limitations highlight the pressing necessity for noninvasive, cost-effective and comprehensive strategies for multicancer early detection (MCED) .  \nLiquid biopsy represents a signiﬁcant advancement in noninvasive cancer screening methodologies7,8. Cell-free DNA (cfDNA) has garnered considerable interest because it effectively reﬂects the genetic and epigenetic signatures associated with tumor biology9, 10. Circulating tumor DNA (ctDNA) originating from tumor cells offers essential insights into cancer detection. Recent developments in next-generation sequencing (NGS) and bioinformatics have facilitated the thorough characterization of cfDNA attributes, encompassing DNA methylation patterns, copy number variations (CNVs) and fragmentomic featur","cbCaifb6BqyXpDh0","https://ap.wps.com/l/cbCaifb6BqyXpDh0","pdf",2488747,14,"English","# Introduction\n## Liquid biopsy and cfDNA background\n## DNA methylation, CNVs, and fragmentomic features","[{\"question\":\"Why is early-stage multicancer detection difficult with circulating tumor DNA?\",\"answer\":\"Low concentration and heterogeneous characteristics of circulating tumor DNA make detection, especially for stage I disease, challenging.\"},{\"question\":\"What are the four cfDNA characteristics integrated in the ensemble model?\",\"answer\":\"The model integrates average methylation fraction, copy number variation, fragment size ratio, and fragment size distribution.\"},{\"question\":\"How well does the assay perform for early-stage cancers?\",\"answer\":\"Sensitivity is 92.3% for stage I and 92.2% for stage II, indicating effectiveness in detecting early-stage cancers.\"}]","Enhanced multicancer screening assay through whole-genome methylation sequencing-based multimodal cell-free DNA analysis | PDF",1790057308,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6093b452322f30db81098f2eb1b5f6d7.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e868ab3e6c0d552be21cb6e436de0d98.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc470cd4e1bbc8d283c8b8f96c836888.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aaef68853b6064dab9fc1ecdae4facb0.webp",980,1301]